Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Editas Medicine
Editas Medicine
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool
Sun, 01/21/24 - 05:01 pm
Editas Medicine
gene editing
CRISPR Therapeutics
Editas and Vertex Ink Deal for Cas9 License for $50M Upfront
BioSpace
Wed, 12/13/23 - 10:07 pm
Editas Medicine
Vertex Pharmaceuticals
Cas9
Casgevy
ASH23: Pharma branding, Editas’ high bar and clinical trial diversity
BioPharma Dive
Mon, 12/11/23 - 10:52 pm
ASH 2023
JNJ
Editas Medicine
cliincal trials
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
BioSpace
Mon, 06/12/23 - 09:58 am
gene editing
Editas Medicine
Vertex Pharmaceuticals
CRISPR Therapeutics
EDIT-301
sickle cell disease
beta thalassemia
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
Mon, 04/10/23 - 11:32 am
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Major readouts on the horizon for small developers
EP Vantage
Fri, 03/31/23 - 10:19 am
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
Thu, 02/16/23 - 11:18 am
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Editas, in next restructuring step, to sell cell therapy work to Shoreline
BioPharma Dive
Thu, 01/19/23 - 07:43 pm
Editas Medicine
natural killer cell therapy
Shoreline Biosciences
Editas finds buyer for iNK programs 10 days after clearing out pipeline
Fierce Biotech
Thu, 01/19/23 - 10:48 am
Editas Medicine
iNK
Shoreline Biosciences
Editas edits pipeline, lays off 20% and says bye to CSO to kick off #JPM23
Endpoints
Mon, 01/9/23 - 10:32 am
JPMHC 2023
Editas Medicine
layoffs
Editas teases tiny sickle cell sample in effort to climb back into gene editing's upper echelon
Fierce Biotech
Tue, 12/6/22 - 10:34 am
Editas Medicine
sickle cell disease
gene editing
EDT-301
Where Will Editas Medicine Be in 1 Year?
Motley Fool
Sun, 11/20/22 - 12:52 pm
Editas Medicine
EDIT-101
Leber's congenital amaurosis
Editas halts lead CRISPR program after efficacy data underwhelm
Endpoints
Thu, 11/17/22 - 12:10 pm
Editas Medicine
CRISPR
EDIT-101
clinical trials
ASH preview – waiting for Editas
EP Vantage
Wed, 11/9/22 - 10:40 am
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101
BioSpace
Wed, 11/2/22 - 10:54 pm
Editas Medicine
EDIT-101
gene therapy
Leber's congenital amaurosis
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets
BioSpace
Tue, 10/18/22 - 10:13 pm
Editas Medicine
gene editing
CRISPR
M&A
oncology
Editas treats first patient in sickle cell trial as FDA lifts partial hold
BioPharma Dive
Fri, 07/29/22 - 10:03 am
Editas Medicine
clinical trials
CRISPR
gene editing
sickle cell disease
Editas’ Novel Sickle Cell Therapeutic Shows Early Promise
BioSpace
Wed, 07/27/22 - 06:39 pm
Editas Medicine
clinical trials
EDIT-301
sickle cell disease
Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
BioPharma Dive
Tue, 06/7/22 - 10:22 am
Editas Medicine
CRISPR
gene editing
Immatics
gamma delta cell therapy
FDA tags Editas' thalassemia cell therapy an orphan drug as it rounds final bend in race to clinic
Fierce Biotech
Sun, 05/15/22 - 11:19 pm
Editas Medicine
FDA
beta thalassemia
EDIT-301
Pages
1
2
3
next ›
last »